Mark S. Diamond - Concepedia

Author

Mark S. Diamond

University of Pennsylvania

Also Known As

Diamond, Mark, Mark Diamond, Mark S Diamond, Mark S. Diamond

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

University of Pennsylvania Washington University in St. Louis Parker Institute for Cancer Immunotherapy Cancer Research Institute Howard Hughes Medical Institute

About

Mark S. Diamond is an author at University of Pennsylvania specializing in immunology, medicine, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	2.7K
2	Immunology	4	4	2.7K
3	Cell Biology	2	2	2.1K
4	Pathology	1	1	593
5	Pharmacology	1	1	20

Mark S. Diamond

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
<i>Batf3</i> Deficiency Reveals a Critical Role for CD8α <sup>+</sup> Dendritic Cells in Cytotoxic T Cell Immunity Kai Hildner, Brian T. Edelson, Whitney E. Purtha, Science Adaptive Immune SystemImmunologyImmunologic MechanismCd4 T Cell ResponsesImmunotherapy	2008	2K
Type I interferon is selectively required by dendritic cells for immune rejection of tumors Mark S. Diamond, Michelle Kinder, Hirokazu Matsushita, The Journal of Experimental Medicine	2011	1K
A critical function for type I interferons in cancer immunoediting Gavin P. Dunn, Allen T. Bruce, Kathleen C. F. Sheehan, Nature Immunology Cancer ImmunosurveillanceImmunologyTumor ImmunityPathologyImmunologic Mechanism	2005	593
Blocking Monoclonal Antibodies Specific for Mouse IFN- <i>α</i> / <i>β</i> Receptor Subunit 1 (IFNAR-1) from Mice Immunized by <i>In Vivo</i> Hydrodynamic Transfection Kathleen C. F. Sheehan, Koon Siew Lai, Gavin P. Dunn, Journal of Interferon & Cytokine Research	2006	259
Lack of immunoediting in murine pancreatic cancer reversed with neoantigen Rebecca A. Evans, Mark S. Diamond, Andrew J. Rech, JCI Insight	2016	178
Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity Alexander H. Morrison, Mark S. Diamond, Ceire Hay, Proceedings of the National Academy of Sciences Adaptive Immune SystemT-regulatory CellImmunologyImmune RegulationImmunodominance	2020	128
Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming Mark S. Diamond, Jeffrey Lin, Robert H. Vonderheide Cancer Immunology Research	2021	26
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma Il‐Kyu Kim, Mark S. Diamond, Salina Yuan, Nature Communications	2024	25
Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma. Brian Andrew Van Tine, Vanessa Eulo, Jacqui Toeniskoetter, Journal of Clinical Oncology Lba11504 BackgroundOncologyPhase Ii TrialSoft Tissue SarcomaMedicine	2023	20
SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES). Patrick J. Grohar, Karla V. Ballman, Rachel S. Heise, Journal of Clinical Oncology	2024	11

Page 1